Jonathan W. Goldman, MD, on SCLC: Tarlatamab Extended-Interval Dosing Regimens
IASLC WCLC 2026
Jonathan W. Goldman, MD, of the University of California, Los Angeles, reviews findings from the phase II DeLLphi-309 study, which examined the efficacy, safety, and pharmacokinetics of tarlatamab extended-interval dosing regimens (20 mg every 3 weeks and 30 mg every 4 weeks) in comparison to the usual dose of 10 mg every 2 weeks in patients with small cell lung cancer (SCLC) (Abstract OA05.01).
Alberto A. Chiappori, MD, of Moffitt Cancer Center, discusses findings from a phase I trial looking at the safety and efficacy of LB2102, an autologous CAR-T cell therapy targeting DLL3 and armored with a dominant-negative TGF-beta receptor, in pretreated patients with small cell lung cancer (SCLC) (Abstract OA05.02).
Adam J. Schoenfeld, MD, of Memorial Sloan Kettering Cancer Center, discusses findings from BNT324-01, an ongoing global phase Ib/II trial looking at pumitamig, an investigational PD-L1 × VEGF-A bispecific antibody, combined with elfetabart drozuntecan (BNT324/DB-1311), an investigational B7-H3–targeted antibody-drug conjugate, with a focus in small cell lung cancer (SCLC) (Abstract OA14.02).
Pedro Rocha, MD, PhD, of Vall d'Hebron University Hospital, presents data from the phase Ib DeLLphi-308 study, which investigated subcutaneous administration of the bispecific T-cell engager tarlatamab—which may improve convenience and produce lower peak serum concentrations, potentially reducing adverse events—compared with its usual intravenous administration among patients with extensive-stage small cell lung cancer (SCLC) (Abstract MO15.07).
Chad G. Rusthoven, MD, of the University of Colorado School of Medicine, presents results from the international phase III SWOG S1827 MAVERICK trial, which showed that brain MRI surveillance alone improved cognitive failure–free survival compared with MRI surveillance plus prophylactic cranial irradiation in patients with small cell lung cancer (SCLC). The findings support MRI surveillance alone as the standard of care for patients with SCLC (Abstract PL02.01).
Ricardo Sales dos Santos, MD, PhD, of the ProPulmão Institute, discusses data from the Third Brazilian Early Lung Cancer Trial (BRELT3). The study found low-dose computed tomography (CT) lung cancer screening using a mobile unit is feasible in socially vulnerable populations in resource-limited settings. Community-based recruitment, particularly through community health workers, improved the inclusion of high-risk and underserved groups, supporting the expansion of organized screening programs to promote equitable access and reduce lung cancer mortality (Abstract MO14.03).
